Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 60, Issue 4, 2011, Pages 544-549

  Aktas, Bilge ^a   Yilmaz, Yusuf ^a   Eren, Fatih ^b   Yonal, Oya ^a   Kurt, Ramazan ^a   Alahdab, Yesim Ozen ^a   Celikel, Cigdem Ataizi ^a   Ozdogan, Osman ^a   Imeryuz, Nese ^a   Kalayci, Cem ^a   Avsar, Erol ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALANINE AMINOTRANSFERASE; APELIN 36; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OBESTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASPIN;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTHROPOMETRY; BIOPSY; BODY MASS INDEX; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; GHRELIN; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHENOTYPE; SERPINS;

EID: 79952988824     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.05.008     Document Type: Article

References (34)

1. Erickson S.K. Nonalcoholic fatty liver disease J Lipid Res 50 Suppl 2009 S412 S416
2. Sass D.A., Chang P., and Chopra K.B. Nonalcoholic fatty liver disease: a clinical review Dig Dis Sci 50 2005 171 180 (Pubitemid 40379159)
3. Almeda-Valdés P., Cuevas-Ramos D., and Aguilar-Salinas C.A. Metabolic syndrome and non-alcoholic fatty liver disease Ann Hepatol 8 Suppl 1 2009 S18 S24
4. Byrne C.D., Olufadi R., Bruce K.D., Cagampang F.R., and Ahmed M.H. Metabolic disturbances in non-alcoholic fatty liver disease Clin Sci (Lond) 116 2009 539 564
5. Grønbaek H., Thomsen K.L., Rungby J., Schmitz O., and Vilstrup H. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes Expert Rev Gastroenterol Hepatol 2 2008 705 711
6. Kim C.H., and Younossi Z.M. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome Cleve Clin J Med 75 2008 721 728
7. Yilmaz Y., Ulukaya E., Gul O.O., Arabul M., Gul C.B., and Atug O. Decreased plasma levels of soluble receptor for advanced glycation end products (sRAGE) in patients with nonalcoholic fatty liver disease Clin Biochem 42 2009 802 807
8. Maury E., and Brichard S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome Mol Cell Endocrinol 314 2010 1 16
9. Marra F., and Bertolani C. Adipokines in liver diseases Hepatology 50 2009 957 969
10. Tsochatzis E.A., Papatheodoridis G.V., and Archimandritis A.J. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy Mediators Inflamm 2009 2009 831670
11. Polyzos S.A., Kountouras J., and Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines Curr Mol Med 9 2009 299 314
12. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects Expert Opin Investig Drugs 17 2008 327 333 (Pubitemid 351578185)
13. Seeger J., Ziegelmeier M., Bachmann A., Lössner U., Kratzsch J., and Blüher M. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters J Clin Endocrinol Metab 93 2008 247 251
14. Kukla M., Zwirska-Korczala K., Hartleb M., Waluga M., Chwist A., and Kajor M. Serum chemerin and vaspin in non-alcoholic fatty liver disease Scand J Gastroenterol 45 2010 235 242
15. Ren A.J., Guo Z.F., Wang Y.K., Lin L., Zheng X., and Yuan W.J. Obestatin, obesity and diabetes Peptides 30 2009 439 444
16. Monteleone P., Serritella C., Martiadis V., Scognamiglio P., and Maj M. Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa J Clin Endocrinol Metab 93 2008 4418 4421 (Pubitemid 352789541)
17. Kleinz M.J., and Davenport A.P. Emerging roles of apelin in biology and medicine Pharmacol Ther 107 2005 198 211 (Pubitemid 40916219)
18. Rayalam S., Della-Fera M.A., Krieg P.A., Cox C.M., Robins A., and Baile C.A. A putative role for apelin in the etiology of obesity Biochem Biophys Res Commun 368 2008 815 819
19. Ercin C.N., Dogru T., Tapan S., Kara M., Haymana C., and Karadurmus N. Plasma apelin levels in subjects with nonalcoholic fatty liver disease Metabolism 2009 10.1016/j.metabol.2009.10.019
20. Hosoya M., Kawamata Y., Fukusumi S., Fujii R., Habata Y., and Hinuma S. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin J Biol Chem 275 2000 21061 21067 (Pubitemid 30481796)
21. Kawamata Y., Habata Y., Fukusumi S., Hosoya M., Fujii R., and Hinuma S. Molecular properties of apelin: tissue distribution and receptor binding Biochim Biophys Acta 1538 2001 162 171 (Pubitemid 32402239)
22. Sörhede Winzell M., Magnusson C., and Ahrén B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice Regul Pept 131 2005 12 17
23. Ringström C., Nitert M.D., Bennet H., Fex M., Valet P., and Rehfeld J.F. Apelin is a novel islet peptide Regul Pept 162 2010 44 51
24. ACE/ADA Task Force on Inpatient Diabetes American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control Diabetes Care 29 2006 1955 1962
25. Grundy S.M., Brewer H.B. Jr, Cleeman J.I., Smith S.C. Jr, Lenfant C., and American Heart Association and National Heart, Lung, and Blood Institute Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation 109 2004 433 438 (Pubitemid 38133916)
26. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., and Cummings O.W. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321 (Pubitemid 40770284)
27. Minoretti P., Falcone C., Calcagnino M., Emanuele E., Buzzi M.P., and Coen E. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina Eur Heart J 27 2006 802 807
28. Dray C., Knauf C., Daviaud D., Waget A., Boucher J., and Buléon M. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice Cell Metabolism 8 2008 437 445
29. Yue P., Jin H., Aillaud-Manzanera M., Deng A.C., Azuma J., and Asagami T. Apelin is necessary for the maintenance of insulin sensitivity Am J Physiol Endocrinol Metab 2009 10.1152/ajpendo.00385.2009
30. Li L., Yang G., Li Q., Tang Y., Yang M., and Yang H. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects Exp Clin Endocrinol Diabetes 114 2006 544 548 (Pubitemid 46087259)
31. Kukla M., Zwirska-Korczala K., Gabriel A., Waluga M., Warakomska I., and Berdowska A. Visfatin serum levels in chronic hepatitis C patients J Viral Hepat 2009 10.1111/j.1365-2893.2009.01174.x
32. Janciauskiene S. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles Biochim Biophys Acta 1535 2001 221 235 (Pubitemid 32241132)
33. Gauldie J., Bonniaud P., Sime P., Ask K., and Kolb M. TGF-beta, Smad3 and the process of progressive fibrosis Biochem Soc Trans 35 2007 661 664 (Pubitemid 47310335)
34. Senolt L., Polanská M., Filková M., Cerezo L.A., Pavelka K., and Gay S. Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis Ann Rheum Dis 2010 10.1136/ard.2009.119735